CanSinoBIO to Contract Manufacture for AstraZeneca
31 Aug 2023
US$ 19.00
CanSino Biologics Inc (CanSinoBIO), a leading vaccine developer in China which has enlisted Qiming Venture Partners...
Related Publications
It has been more than a decade since MBK Partners (MBK) completed the largest buyout in Asia in 2015, the £4.2 bn...
MiniMax Group Inc, an AI foundation model company with shareholders including IDG Capital (IDG), HongShan Capital ......
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.